多发性骨髓瘤中的新型免疫标:生物相关性和治疗潜力
Jana Kotulová1,2, Klára Baďurová1,2, Zuzana Chyra1,2
1Department of Haematooncology, University Hospital Ostrava, Ostrava, Czech Republic.
Biomarker research
|July 2, 2025
概括
新兴的免疫点为多发性骨髓瘤治疗提供了新的希望,通过克服抗原逃逸和瘤外毒性. 像LILRB4和SEMA4A这样的有希望的标显示出下一代免疫疗法的潜力,改善了患者的治疗结果.
科学领域:
- 血液恶性瘤研究研究
- 免疫疗法开发 免疫疗法开发
- 蛋白质组学和体组学技术
背景情况:
- 多发性骨髓瘤 (MM) 是由复杂的遗传和微环境因素驱动的,导致治疗耐药性.
- 目前针对BCMA等抗原的治疗方法面临诸如抗原逃逸,耐药性和瘤外毒性等挑战.
- 迫切需要新的治疗策略来改善MM患者的治疗结果.
研究的目的:
- 审查多发性骨髓瘤 (MM) 的新兴免疫点.
- 总结它们的生物功能,MM病原发生中的作用,以及治疗干预的潜力.
- 突出下一代免疫疗法的有希望的目标.
主要方法:
- 在临床或临床前发展早期对新兴免疫点的审查.
- 专注于十五个目标,强调LILRB4,SEMA4A,ITGB7,CCR1和CD70.
- 分析生物功能,疾病作用和治疗潜力.
主要成果:
- 确定了15个新兴的免疫点,有可能用于MM治疗.
- 特别强调LILRB4,SEMA4A,ITGB7,CCR1和CD70作为特别有希望的.
- 临床前和早期临床数据表明有利的安全性,高瘤特异性和克服耐药性的机制.
结论:
- 新兴的免疫标为下一代MM免疫疗法提供了重大潜力.
- 这些目标可以最大限度地降低非瘤毒性,降低复发风险.
- 这些目标的进一步发展可能会导致改善患者的治疗结果和减少不良影响.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
13.2K
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
8.7K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
667
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
667
Cytotoxic T Cells-mediated Immune Response
2.4K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
2.4K
